Search research articles
Contact Us
Filters
Showing results (251-260 of 253) with videos related to
Page
of 26
Sort By:
You have reached the last page of results.
This site can display upto 253 results.
Atherosclerosis
|
August 16, 2025
Apolipoprotein CIII in statin-treated type 2 diabetic patients: Its implications for plaque progression and instability: The pre-specified analysis from the OPTIMAL randomized controlled trial
Satoshi Kitahara, Yu Kataoka, Stephen J Nicholls, et al.
JAMA
|
June 26, 2019
Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial
Hirotoshi Watanabe, Takenori Domei, Takeshi Morimoto, et al.
Cardiovascular Intervention and Therapeutics
|
February 23, 2020
Details on the effect of very short dual antiplatelet therapy after drug-eluting stent implantation in patients with high bleeding risk: insight from the STOPDAPT-2 trial
Hirotoshi Watanabe, Takenori Domei, Takeshi Morimoto, et al.
Page
of 26
Search research articles
Search
Showing results (251-260 of 253) with videos related to
Sort By:
Page
of 26
You have reached the last page of results.
This site can display upto 253 results.
Atherosclerosis
|
August 16, 2025
Apolipoprotein CIII in statin-treated type 2 diabetic patients: Its implications for plaque progression and instability: The pre-specified analysis from the OPTIMAL randomized controlled trial
Satoshi Kitahara, Yu Kataoka, Stephen J Nicholls, et al.
JAMA
|
June 26, 2019
Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial
Hirotoshi Watanabe, Takenori Domei, Takeshi Morimoto, et al.
Cardiovascular Intervention and Therapeutics
|
February 23, 2020
Details on the effect of very short dual antiplatelet therapy after drug-eluting stent implantation in patients with high bleeding risk: insight from the STOPDAPT-2 trial
Hirotoshi Watanabe, Takenori Domei, Takeshi Morimoto, et al.
Page
of 26